Ziccum develops new dry powder preparations of biological pharmaceuticals – unlocking new patents and new markets.
Ziccum AB was set up in 2017 by its original parent company, Inhalation Sciences AB, to develop and commercialize the patented spray drying technology LaminarPace. The system was invented Dr Per Gerde, Associate Professor of Inhalation Toxicology at the Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
The future is in dry powders
LaminarPace was initially developed to formulate dry powders for use in Inhalation Sciences’ aerosol generating platform PreciseInhale. Dry-form pharmaceuticals are preferred for the vast majority of pharma projects. Dry powder is more stable, durable and cost-effective to transport and handle than liquid solutions. It requires no expensive cold chain infrastructure for distribution, and opens up new treatments like biologics to new patients and markets.
“We knew from the beginning that LaminarPace’s capabilities went way, way beyond aerosols. That’s why we decided to spin it out from its parent company—Inhalation Sciences.” Fredrik Sjövall, Chairman, Ziccum AB.
Over the course of LaminarPace’s development, as it successfully formulated over 100 substances (including temperature-sensitive ones like proteins and antibodies) its capabilities beyond formulation for aerosols became clear.
Currently, 80% of biologic therapies are formulated as liquid solutions, making them costly and difficult to handle and transport—despite clear medical benefits and significant projected growth. LaminarPace technology is unique in being able to formulate temperature-sensitive materials, such as biologic therapies like proteins and peptides, into robust dry powders.
New products and patents
Harnessing the Intellectual Property rights on new dry powder versions of therapies is a key component of LaminarPace’s business and scientific potential. Ziccum intends to use its LaminarPace technology to begin creating new versions of dry powder therapies—as old therapies go off-patent, and new ones are developed. Each substance will be available for licensing for pharmaceutical companies looking to build and protect their product portfolio.
“With every new project, and every new substance formulated, we see how LaminarPace can open up new patents, markets and therapies. We’re a small, driven team with a big technology with big capabilities. And we’re still only at the beginning.” Göran Conradson, CEO Ziccum AB.